Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQT Study of Lucerastat in Healthy Subjects
NCT03832452Phase 1Completed
- Sponsor
- Idorsia
- Start
- Feb 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lucerastat in Fabry disease (FD) (6 arms), sponsored by Idorsia. Primary endpoint: Placebo-corrected change-from-baseline QTcF at 37 hours. Started Feb 2019; status: completed.
02
Drugs
lucerastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT03832452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03832452.